(R)-(1-ethoxycarbonyl-ethyl)-acetoacetate | 143444-49-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: (R)-(1-ethoxycarbonyl-ethyl)-acetoacetate
• 英文别名: (R)-1-ethoxy-1-oxopropan-2-yl 3-oxobutanoate；[(2R)-1-ethoxy-1-oxopropan-2-yl] 3-oxobutanoate
• CAS: 143444-49-9
• 化学式: C₉H₁₄O₅
• 分子量: 202.207
• InChiKey: BTCYFWDWPKLJCC-SSDOTTSWSA-N

物化性质

• 沸点：
  274.0±15.0 °C(Predicted)
• 密度：
  1.113±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-(1-ethoxycarbonyl-ethyl)-acetoacetate 在 氨 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 35.0h， 生成 (R)-(1-ethoxycarbonyl-ethyl)-(S)-1,4-dihydro-2,6-dimethyl-4-(2,3-dichlorophenyl)-5-(1,3,4-oxadiazol-2-yl)-pyridine-3-carboxylate
  参考文献：
  名称：

  Calcium- and calmodulin-antagonism of elnadipine derivatives: comparative SAR

  摘要：

  The Ca2+-antagonistic properties of elnadipine derivatives have been quantified by means of binding experiments in bovine cerebral cortex membranes using H-3-nitrendipine. Competition experiments have shown a 308-fold concentration range of K(i)-values (2.9 x 10(-10) to 8.9 x 10(-8)) for elnadipine derivatives and a eudismic ratio for elnadipine and its (+)-enantiomer of 448. Calmodulin (CaM)-antagonistic properties have been measured in the test system of CaM-stimulated phosphodiesterase. The concentration range of IC50 values only amounts to 9 (5 x 10(-7) to 4.5 x 10(-6) M). In contrast to Ca2+-antagonism, enantioselectivity of CaM-inhibition by elnadipine is negligible. CaM-antagonistic potency of elnadipine derivatives is diminished by a factor of 10 to 5000 as compared to their Ca2+-antagonistic potency. The following conclusions regarding structural determinants of Ca2+- and CaM-antagonistic properties can be made: lipophilic substituents of the oxadiazole in 5-position of the dihydropyridine (DHP) ring increase the CaM-antagonistic and decrease the Ca2+-antagonistic potency: correspondingly the unsubstituted compound is the strongest Ca2+- and the weakest CaM-antagonist; 1,3,4-oxadiazole substitution is superior to 1,2,4-oxadiazole as regards Ca2+- and CaM-antagonistic potency.

  DOI：

  10.1016/0223-5234(92)90006-m
• 作为产物：
  描述：

  D-乳酸乙酯 在 2,2,6-三甲基-4H-1,3-二英-4-酮 作用下， 反应 4.0h， 生成 (R)-(1-ethoxycarbonyl-ethyl)-acetoacetate
  参考文献：
  名称：

  [EN] HEPATITIS B ANTIVIRAL AGENTS
  [FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B

  摘要：

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药：这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。

  公开号：

  WO2017011552A1

文献信息

• HEPATITIS B ANTIVIRAL AGENTS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20170355701A1

  公开（公告）日：2017-12-14

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）的化合物或其药学上可接受的盐：这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于给患有HBV感染的受试者使用。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• [EN] PROCESSES FOR PREPARING DIHYDROPYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉS DE PRÉPARATION DE DÉRIVÉS DE DIHYDROPYRIMIDINE, ET INTERMÉDIAIRES DE CEUX-CI
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015078391A1

  公开（公告）日：2015-06-04

  The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (la), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.

  本发明涉及制备具有式（I）的二氢嘧啶化合物或具有式（la）的其互变异构体，以及其中间体的过程。本发明的工艺具有操作简单、产品光学纯度高、收率高且方便的工作提取，适用于工业生产。
• PROCESSES FOR PREPARING DIHYDROPYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20160264562A1

  公开（公告）日：2016-09-15

  The present invention refers to processes for preparing a dihydropyrimidine compound having Formula (I), or a tautomer thereof having Formula (la), as well as a intermediate thereof. The process of the invention has simple operation, high optical purity of product, high yield and convenient work-up, which is suitable for industrial production.

  本发明涉及制备具有式（I）的二氢嘧啶化合物或具有式（la）的其互变异构体，以及其中间体的过程。本发明的工艺具有操作简单、产物光学纯度高、收率高且便于工作的优点，适用于工业生产。
• [EN] PHENYLDIHYDROPYRIMIDINE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ PHÉNYLDIHYDROPYRIMIDINE ET SON UTILISATION<br/>[ZH] 苯基二氢嘧啶类化合物及其应用
  申请人：[en]HEPAGENE THERAPEUTICS (HK) LIMITED;[zh]和博医药有限公司

  公开号：WO2022166923A1

  公开（公告）日：2022-08-11

  如式I 所示的苯基二氢嘧啶类化合物、其互变异构体或其药学上可接受的盐。该苯基二氢嘧啶类化合物具有较好的抗HBV活性，可用于制备治疗和/或预防HBV感染的药物。
• US9617252B2
  申请人：——

  公开号：US9617252B2

  公开（公告）日：2017-04-11